Literature DB >> 32386053

Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis.

Cristina Díez1,2, Juan Berenguer1,2, Luis Ibañez-Samaniego2,3,4, Elba Llop4,5,6, Leire Pérez-Latorre1,2, María V Catalina2,3,4, Víctor Hontañón7,8, María A Jiménez-Sousa9, Teresa Aldámiz-Echevarría1,2, Javier Martínez4,10,11, José Luis Calleja4,5,6,12, Agustín Albillos4,10,11,13, José M Bellón2, Salvador Resino9, Juan González-García7,8, Rafael Bañares2,3,4,14.   

Abstract

This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HCV; cirrhosis; direct-acting antiviral agents; eradication; portal hypertension

Year:  2020        PMID： 32386053     DOI： 10.1093/cid/ciaa502

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  5 in total

1.  Cerebrovascular Complications and Vessel Wall Imaging in COVID-19 Encephalopathy-A Pilot Study.

Authors:  Marjolaine Uginet; Gautier Breville; Jérémy Hofmeister; Paolo Machi; Patrice H Lalive; Andrea Rosi; Aikaterini Fitsiori; Maria Isabel Vargas; Frederic Assal; Gilles Allali; Karl-Olof Lovblad
Journal:  Clin Neuroradiol       Date:  2021-03-26       Impact factor: 3.649

Review 2.  Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response.

Authors:  Sara Cuesta-Sancho; Mercedes Márquez-Coello; Francisco Illanes-Álvarez; Denisse Márquez-Ruiz; Ana Arizcorreta; Fátima Galán-Sánchez; Natalia Montiel; Manuel Rodriguez-Iglesias; José-Antonio Girón-González
Journal:  World J Hepatol       Date:  2022-01-27

3.  HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.

Authors:  Óscar Brochado-Kith; Isidoro Martínez; Juan Berenguer; Juan González-García; Sergio Salgüero; Daniel Sepúlveda-Crespo; Cristina Díez; Víctor Hontañón; Luis Ibañez-Samaniego; Leire Pérez-Latorre; Amanda Fernández-Rodríguez; María Ángeles Jiménez-Sousa; Salvador Resino
Journal:  Front Immunol       Date:  2021-08-23       Impact factor: 7.561

4.  Screening and surveillance of oesophageal varices in patients with HCV-positive liver cirrhosis successfully treated by direct-acting antiviral agents.

Authors:  Alessia Ciancio; Davide Giuseppe Ribaldone; Rossella Salamone; Mauro Bruno; Stefania Caronna; Wilma Debernardi Venon; Chiara Giordanino; Alessandra Mondardini; Alessandro Musso; Marco Pennazio; Emanuela Rolle; Marco Sacco; Tatiana Sprujevnik; Claudio De Angelis; Giorgio Maria Saracco
Journal:  Liver Int       Date:  2022-03-07       Impact factor: 8.754

Review 5.  Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?

Authors:  Giorgio Maria Saracco; Alfredo Marzano; Mario Rizzetto
Journal:  Biomedicines       Date:  2022-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.